Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27460431 | 0.83 | — | — | |
| SCHEMBL28123001 | 0.79 | — | — | |
| SCHEMBL27776621 | 0.75 | HSD17B10 (0.35) | — | |
| SCHEMBL10717017 | 0.73 | LMNA (0.35) | LMNATHRB | |
| Ether SCHEMBL7950584 | 0.72 | — | — | |
| SCHEMBL13409413 | 0.71 | — | — | |
| SCHEMBL13103905 | 0.69 | — | — | |
| SCHEMBL22697441 | 0.69 | LMNA (0.32) | LMNA | |
| Phosphine SCHEMBL8061423 | 0.69 | MEN1 (0.33) | — | |
| Isopropyl Alcohol SCHEMBL1408797 | 0.65 | LMNA (0.38) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170080409-A1 | CATALYSTS FOR EPOXIDE CARBONYLATION | NOVOMER, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-8324257-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIF18B | LMNA 1861/4885THRB 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.